This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why Universal Health Services (UHS) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Universal Health Services (UHS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Tenet Healthcare Corporation (THC) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Tenet (THC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Accuray (ARAY) Q4 Earnings Lag Estimates, Gross Margin Shrinks
by Zacks Equity Research
Despite improving product sales, Accuray (ARAY) reports mixed fourth-quarter fiscal 2024 results.
Stereotaxis (STXS) Receives European Approval for GenesisX
by Zacks Equity Research
Stereotaxis (STXS) gains CE mark for GenesisX and plans to launch the system in 2025.
Solventum's (SOLV) Q2 Earnings Beat Estimates, ' 24 View Raised
by Zacks Equity Research
Solventum's (SOLV) second-quarter results show resilience in MedSurg and Health Information Systems. Its shrinking margins pose concerns.
Baxter's (BAX) Vantive Divestiture to Aid Its Operational Sales
by Zacks Equity Research
Baxter (BAX) announces the divestiture of its Kidney Care segment, Vantive, to a global investment firm Carlyle.
Cardinal Health (CAH) Beats on Q4 Earnings, Ups '24 EPS View
by Zacks Equity Research
Cardinal Health's (CAH) fourth-quarter fiscal 2024 results benefit from solid profit growth in Pharmaceutical and Specialty Solutions. The company raises its EPS guidance for fiscal 2024.
Reasons to Retain Veeva Systems (VEEV) in Your Portfolio Now
by Zacks Equity Research
Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock. However, data security threats and escalating costs are concerning.
Universal Health Services, Inc. (UHS) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Universal Health Services (UHS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Reasons to Retain Ecolab (ECL) Stock in Your Portfolio Now
by Zacks Equity Research
Ecolab's (ECL) focus on cost efficiency programs raises optimism about the stock.
Neuronetics' (STIM) Latest Deal to Aid Mental Health Treatments
by Harshit Gupta
Neuronetics (STIM) announces the acquisition of Greenbrook to provide better care to patients suffering from mental health conditions.
Stryker (SYK) to Acquire care.ai to Boost AI-Driven Healthcare
by Zacks Equity Research
Stryker's (SYK) acquisition of care.ai is set to enhance its healthcare IT offerings with AI-assisted virtual care workflows and smart room technology.
Fast-paced Momentum Stock Universal Health Services (UHS) Is Still Trading at a Bargain
by Zacks Equity Research
Universal Health Services (UHS) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Reasons to Retain Cardinal Health (CAH) in Your Portfolio Now
by Zacks Equity Research
Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.
Smith & Nephew (SNN) Partners InfuSystem for Renasys Edge
by Zacks Equity Research
Smith & Nephew (SNN) inks a three-year agreement with InfuSystem (INFU) to distribute its RENASYS EDGE negative pressure wound therapy system.
Here's Why You Should Retain Accuray (ARAY) Stock for Now
by Zacks Equity Research
Accuray's (ARAY) solid product demand raises optimism about the stock.
5 Best of the Best Stock Picks: Strong Buys and VGM of A
by Tracey Ryniec
HRB, ANF, POWL, EME and UHS have value, growth, momentum, and rising earnings estimates.
J&J's (JNJ) DePuy Synthes' TriLEAP System to Aid Ankle Surgery
by Zacks Equity Research
Johnson & Johnson's (JNJ) DePuy Synthes announces the launch of its TriLEAP System, which is likely to provide better orthopedic solutions to foot and ankle surgeons.
Bruker (BRKR) Partners With NovAliX to Boost Drug Discovery
by Zacks Equity Research
Bruker (BRKR) invests in NovAliX to accelerate advancements in drug discovery, combining cutting-edge biophysical methods and technologies to develop new treatments and enhance biopharma solutions.
Reasons to Hold Patterson Companies (PDCO) in Your Portfolio Now
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.
Stryker's (SYK) Pangea System to Enhance Plating Solutions
by Zacks Equity Research
Stryker (SYK) announces the launch of its Pangea Plating System, which is likely to provide solutions for internal fixation and stabilization of bone fractures.
PacBio (PACB) Q2 Earnings Beat Estimates, Revenues Down Y/Y
by Zacks Equity Research
PacBio's (PACB) Product revenues decline in the second quarter of 2024. However, Consumable and Service and other revenues increase year over year.
Vicarious Surgical (RBOT) Partners LSU Health New Orleans
by Zacks Equity Research
Vicarious Surgical (RBOT) teams up with LSU Health New Orleans to advance its V1.0 surgical robot. It aims to file for FDA approval by 2026.
McKesson (MCK) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
McKesson's (MCK) first-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.
Smith & Nephew (SNN), HOPCo to Enhance Musculoskeletal Care
by Zacks Equity Research
Smith & Nephew (SNN) announces a collaboration with HOPCo to focus on enhancing solutions for ASC customers, physicians, and patients through the latter's digital health and analytics platforms.